What the FDA labels say about taking them together
Denosumab and lenvatinib
Lenvatinib's FDA label of June 30, 2026 names denosumab in its warnings and precautions section; the denosumab labels PlainMeds reads (4) do not name lenvatinib. The lenvatinib label: “Concomitant exposure to other risk factors, such as bisphosphonates, denosumab, dental disease or invasive dental procedures, may increase the risk of ONJ.”
Check it at the source: the denosumab FDA label on DailyMed (effective June 23, 2026, Amgen, Inc); the lenvatinib FDA label on DailyMed (effective June 30, 2026, Eisai Inc.).
What does the denosumab label say about lenvatinib?
Denosumab's label (effective June 23, 2026) and its 3 other brand-application labels do not name lenvatinib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (XGEVA), Amgen, Inc, effective June 23, 2026 (SPL set 628f0998-1206-4001-aeee-18133aa9f3bf), via openFDA; the full label on DailyMed
What does the lenvatinib label say about denosumab?
Lenvatinib label, warnings and precautionsConcomitant exposure to other risk factors, such as bisphosphonates, denosumab, dental disease or invasive dental procedures, may increase the risk of ONJ.
Source: FDA drug label (Lenvima), Eisai Inc., effective June 30, 2026 (SPL set f4bedd21-efde-44c6-9d9c-b48b78d7ed1e), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Denosumab | Lenvatinib | |
|---|---|---|
| Labeled for | Osteoporosis | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $1,862.74 per mL 60 mg/mL syringe | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once